Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 157, Issue 4, pp 520–523 | Cite as

Components of the RANK/RANKL/OPG System, IL-6, IL-8, IL-16, MMP-2, and Calcitonin in the Sera of Patients with Bone Tumors

  • N. E. Kushlinskii
  • Yu. S. Timofeev
  • Yu. N. Solov’ev
  • E. S. Gerstein
  • N. V. Lyubimova
  • I. V. Bulycheva
Article

Serum levels of sRANKL, RANK, OPG, IL-8, IL-6, IL-16, MMP-2, and calcitonin were measured by ELISA in patients with malignant, borderline, and benign bone tumors and in healthy individuals (control). Serum levels of RANK, OPG, IL-8, IL-6, and the OPG/sRANKL ratio were signifi cantly higher, while the level of MMP-2 was signifi cantly lower in patients with bone tumors than in controls. Serum concentration of IL-16 in osteosarcoma patients was signifi cantly lower than in chondrosarcoma patients. No signifi cant differences between bone sarcomas of different differentiation were detected for any of the studied markers. Calcitonin level depended on the tumor location and type.

Keywords

bone tumors RANK/RANKL/OPG system interleukin-16, -6, -8 matrix metalloproteinase-2 calcitonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. S. Gerstein, E. A. Korotkova, V. V. Prorokov, and N. E. Kushlinsky, Bull. Exp. Biol. Med., 145, No. 3, 362-366 (2008).Google Scholar
  2. 2.
    E. S. Gerstein, N. V. Levkina, M. A. Digayeva, et al., Bull. Exp. Biol. Med., 149, No. 5, 628-631 (2010).Google Scholar
  3. 3.
    N. E. Kushlinsky, Yu. N. Solovyov, I. V. Babkina, et al., Bull. Exp. Biol. Med., 149, No. 2, 233-235 (2010).PubMedGoogle Scholar
  4. 4.
    ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed., Washington D. C. (2008), P. 537.Google Scholar
  5. 5.
    J. Costa-Rodriguez, C. A. Teixeira, and M. H. Fernandes, Clin. Exp. Metastasis, 28, No. 6, 505-514 (2011).CrossRefGoogle Scholar
  6. 6.
    W. C. Dougall, Clin. Cancer Res., 18, No. 5, 326-335 (2012).PubMedCrossRefGoogle Scholar
  7. 7.
    D. Hanahan and R. A. Weinberg, Cell, 144, No. 5, 646-674 (2011).PubMedCrossRefGoogle Scholar
  8. 8.
    C. J. Hsu, T. Y. Lin, C. C. Kuo, et al., J. Cell. Biochem., 111, No. 1, 138-147 (2010).PubMedCrossRefGoogle Scholar
  9. 9.
    H. L. Jorgensen, P. Kusk, B. Madsen, et al., J. Bone Miner. Metab., 22, No. 2, 132-138 (2004).PubMedCrossRefGoogle Scholar
  10. 10.
    J. A. Lee, J. S. Jung, D. H. Kim, et al., Pediatr. Blood Cancer, 56, No. 5, 738-743 (2011).PubMedCrossRefGoogle Scholar
  11. 11.
    B. Liu, S. F. Yu, and T. J. Li, J. Oral Pathol. Med., 32, No. 6, 367-375 (2003).PubMedCrossRefGoogle Scholar
  12. 12.
    G. R. Mundy, Nat. Rev. Cancer, 2, No. 8, 584-593 (2002).PubMedCrossRefGoogle Scholar
  13. 13.
    P. Rutkowski, J. Kamińska, M. Kowalska, et al., J. Surg. Oncol., 84, No. 3, 151-159 (2003).PubMedCrossRefGoogle Scholar
  14. 14.
    E. Terpos, R. Szydlo, J. F. Apperley, et al., Blood, 102, No. 3, 1064-1069 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • N. E. Kushlinskii
    • 1
  • Yu. S. Timofeev
    • 1
  • Yu. N. Solov’ev
    • 1
  • E. S. Gerstein
    • 1
  • N. V. Lyubimova
    • 1
  • I. V. Bulycheva
    • 1
  1. 1.N. N. Blokhin Russian Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations